Halyard Health (NYSE:HYH) updated its FY18 earnings guidance on Wednesday. The company provided EPS guidance of $1.65-$1.85 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.26.
A number of brokerages have commented on HYH. Zacks Investment Research raised shares of Halyard Health from a sell rating to a hold rating in a research note on Friday. Morgan Stanley lifted their price target on shares of Halyard Health from $48.50 to $52.00 and gave the stock an underweight rating in a research note on Thursday. Deutsche Bank lifted their price target on shares of Halyard Health from $42.00 to $50.00 and gave the stock a buy rating in a research note on Thursday. Stifel Nicolaus lifted their price target on shares of Halyard Health from $52.00 to $58.00 and gave the stock a buy rating in a research note on Thursday. Finally, KeyCorp lifted their price target on shares of Halyard Health from $61.00 to $62.00 and gave the stock an overweight rating in a research note on Thursday. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of Buy and a consensus price target of $55.20.
Get Halyard Health alerts:
HYH stock opened at $52.10 on Friday. Halyard Health has a 12 month low of $35.24 and a 12 month high of $54.09. The company has a debt-to-equity ratio of 0.43, a current ratio of 3.22 and a quick ratio of 2.74. The stock has a market cap of $2,434.21, a P/E ratio of 19.95, a PEG ratio of 3.33 and a beta of 1.62.
Halyard Health (NYSE:HYH) last released its quarterly earnings results on Wednesday, May 2nd. The medical instruments supplier reported $0.76 EPS for the quarter, topping analysts’ consensus estimates of $0.17 by $0.59. Halyard Health had a net margin of 7.72% and a return on equity of 7.90%. The firm had revenue of $156.40 million during the quarter, compared to analysts’ expectations of $155.08 million. During the same period in the previous year, the company earned $0.48 EPS. The firm’s revenue for the quarter was up 7.3% compared to the same quarter last year. research analysts expect that Halyard Health will post 1.75 earnings per share for the current year.
Halyard Health Company Profile
Halyard Health, Inc operates as a medical technology company that focuses on eliminating pain, speeding recovery, and preventing infection for healthcare providers and patients worldwide. Its Medical Devices segment provides a portfolio of products that focuses on respiratory and digestive health, along with surgical and interventional pain management.